When the Human Genome Project and State Street collide

From

View current issue Submit your manuscript

Take a look back to prepare for the next generation of biotechnology patent litigation.

This is a preview of subscription content, log in via an institution to check access.

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Auth, D.R. Nat. Biotechnol. 15, 911 (1997).
Article CAS Google Scholar
149 F.3d 1368 (Fed. Cir. 1998), cert. denied, 525 U.S. 1093 (1999).
991 F.2d 781, 784 (Fed. Cir. 1993); see also In re Deuel, 51 F.3d 1552 (Fed. Cir. 1995).
31 U.S.P.Q. 2d 1027 (Bd Pt. App. & Int. 1993).
927 F.2d 1200, 1206 (Fed. Cir.), cert. denied sub. nom, Genetics Inst. v. Amgen, 502 U.S. 856 (1991).
188 F.3d 1362, 1375 (Fed. Cir. 1999).
In re Vaeck, 947 F.2d 488, 496 (Fed. Cir. 1991).
119 F.3d 1559 (Fed. Cir. 1997).
Kowalski, T.J. Nat. Biotechnol. 18, 349–350 (2000).
Article CAS Google Scholar

Scott D. Locke is an associate and David A. Kalow is a partner at Kalow & Springut LLP, 488 Madison Avenue, New York, 10022, NY
Scott D. Locke & David A. Kalow

Authors

Scott D. Locke
View author publications
You can also search for this author in PubMed Google Scholar
David A. Kalow
View author publications
You can also search for this author in PubMed Google Scholar

Locke, S., Kalow, D. When the Human Genome Project and State Street collide. Nat Biotechnol 18, 1009–1010 (2000). https://doi.org/10.1038/79281

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.